匹莫范色林（Nuplazid）：一种治疗帕金森病相关幻觉和妄想的药物。
Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease.
作者信息
Cruz Martin Paspe
出版信息
P T. 2017 Jun;42(6):368-371.
Abstract
Pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Parkinson's disease.
摘要
匹莫范色林（Nuplazid）用于治疗与帕金森病相关的幻觉和妄想。
相似文献
1
Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease.
P T. 2017 Jun;42(6):368-371.
2
The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
J Clin Psychiatry. 2017 Jun;78(6):e668-e673. doi: 10.4088/JCP.16r11119.
3
The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102.
4
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Ann Pharmacother. 2017 Jun;51(6):479-487. doi: 10.1177/1060028017693029. Epub 2017 Feb 1.
5
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Schizophr Res. 2019 Jun;208:217-220. doi: 10.1016/j.schres.2019.02.018. Epub 2019 Mar 2.
6
Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.
Neuropsychiatr Dis Treat. 2017 Mar 8;13:737-744. doi: 10.2147/NDT.S108948. eCollection 2017.
7
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17.
8
Pimavanserin: First Global Approval.
Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9.
9
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Curr Psychiatry Rep. 2018 Jan 27;20(1):3. doi: 10.1007/s11920-018-0869-z.
10
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1.
引用本文的文献
1
Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.
Clin Park Relat Disord. 2025 May 12;12:100342. doi: 10.1016/j.prdoa.2025.100342. eCollection 2025.
2
Impact of pimavanserin on prescribing practices in parkinson disease.
Clin Park Relat Disord. 2025 Mar 16;12:100317. doi: 10.1016/j.prdoa.2025.100317. eCollection 2025.
3
Tailoring adsorbents for levodopa detection: a DFT study on Pt-encapsulated fullerene systems.
RSC Adv. 2024 Aug 28;14(37):27424-27437. doi: 10.1039/d4ra03526g. eCollection 2024 Aug 22.
4
Pimavanserin Use in Lewy Body Dementia: A Case Report Demonstrating the Medication's Efficacy.
Cureus. 2023 Oct 2;15(10):e46356. doi: 10.7759/cureus.46356. eCollection 2023 Oct.
5
The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders.
Front Psychiatry. 2023 Feb 16;14:1124796. doi: 10.3389/fpsyt.2023.1124796. eCollection 2023.
6
Effect of Pimavanserin on the Respiratory Arousal Threshold from Sleep: A Randomized Trial.
Ann Am Thorac Soc. 2022 Dec;19(12):2062-2069. doi: 10.1513/AnnalsATS.202205-419OC.
7
Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
Neurol Ther. 2022 Dec;11(4):1571-1582. doi: 10.1007/s40120-022-00388-y. Epub 2022 Jul 29.
8
Identification of Potential Parkinson's Disease Drugs Based on Multi-Source Data Fusion and Convolutional Neural Network.
Molecules. 2022 Jul 26;27(15):4780. doi: 10.3390/molecules27154780.
9
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
CNS Drugs. 2022 Jan;36(1):17-30. doi: 10.1007/s40263-021-00877-y. Epub 2021 Nov 17.
10
Pharmacological Management of Neuropsychiatric Symptoms of Dementia.
Curr Treat Options Psychiatry. 2020 Dec;7(4):489-507. doi: 10.1007/s40501-020-00233-9. Epub 2020 Sep 2.
本文引用的文献
1
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1.
2
Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease.
Neurol Clin Pract. 2012 Dec;2(4):267-274. doi: 10.1212/CPJ.0b013e318278be9b.
3
Prevalence of psychotic symptoms in a community-based Parkinson disease sample.
Am J Geriatr Psychiatry. 2012 Feb;20(2):123-32. doi: 10.1097/JGP.0b013e31821f1b41.
4
Quetiapine in the treatment of psychosis in Parkinson's disease.
Ther Adv Neurol Disord. 2010 Nov;3(6):339-50. doi: 10.1177/1756285610389656.
5
A 12-year population-based study of psychosis in Parkinson disease.
Arch Neurol. 2010 Aug;67(8):996-1001. doi: 10.1001/archneurol.2010.166.
6
Epidemiology of psychosis in Parkinson's disease.
J Neurol Sci. 2010 Feb 15;289(1-2):12-7. doi: 10.1016/j.jns.2009.08.014. Epub 2009 Sep 8.
7
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.
Mov Disord. 2007 Jun 15;22(8):1061-8. doi: 10.1002/mds.21382.
8
Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.
Eur Neuropsychopharmacol. 2007 Feb;17(3):165-71. doi: 10.1016/j.euroneuro.2006.08.007. Epub 2006 Oct 27.
9
The malignant course of "benign hallucinations" in Parkinson disease.
Arch Neurol. 2006 May;63(5):713-6. doi: 10.1001/archneur.63.5.713.
10
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
JAMA. 2005 Oct 19;294(15):1934-43. doi: 10.1001/jama.294.15.1934.
Zotero 插件